Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

被引:124
作者
Sakamoto, Yoshihiro
Sano, Takeshi
Shimada, Kazuaki
Esaki, Minoru
Saka, Makoto
Fukagawa, Takeo
Katai, Hitoshi
Kosuge, Tomoo
Sasako, Mitsuru
机构
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Surg Div, Chuo Ku, Tokyo, Japan
[2] Natl Canc Ctr, Gastr Surg Div, Tokyo, Japan
关键词
liver metastasis; gastric cancer; hepatectomy; surgical indication;
D O I
10.1002/jso.20739
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal. The purpose of this study was to review our recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery. Study Design: The outcomes of 37 patients with LMGC who underwent hepatectomy between 1990 and 2005 were assessed. No extrahepatic distant metastasis and feasibility of macroscopic curative resection were requisite indications for surgery. The prognostic values of clinicopathological factors were assessed by univariate and multivariate analyses. Results: There was no in-hospital mortality. The median survival time and overall 5-year survival rate after hepatectomy of the patients with LMGC were 31 months and 11%, respectively. Intrahepatic recurrence following hepatectomy was found in 23 patients (62%). Variables independently associated with poor survival were bilobar metastasis (P = 0:002, Cl = 1.9-16.3) and a maximum tumor diameter of >= 4 cm (P = 0.006, CI = 1.4-7:7). The depth of the primary tumor and the timing of metastasis were not associated with survival. Conclusions: Surgical resection for LMGC may be indicated in patients with unilobar metastasis and/or tumors less than 4 cm in diameter. Synchronous metastasis is not a contraindication for hepatectomy.
引用
收藏
页码:534 / 539
页数:6
相关论文
共 20 条
[1]   Benefits and limits of hepatic resection for gastric metastases [J].
Ambiru, S ;
Miyazaki, M ;
Ito, H ;
Nakagawa, K ;
Shimizu, H ;
Yoshidome, H ;
Shimizu, Y ;
Nakajima, N .
AMERICAN JOURNAL OF SURGERY, 2001, 181 (03) :279-283
[2]   MANAGEMENT OF PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM COLORECTAL AND GASTRIC-CANCER EMPLOYING AN IMPLANTABLE PORT SYSTEM [J].
ARAI, Y ;
ENDO, T ;
SONE, Y ;
TOHYAMA, N ;
INABA, Y ;
KOHNO, S ;
ARIYOSHI, Y ;
KIDO, C .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 :S99-S102
[3]   Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients [J].
Elias, D ;
de Albuquerque, AC ;
Eggenspieler, P ;
Plaud, B ;
Ducreux, M ;
Spielmann, M ;
Theodore, C ;
Bonvalot, S ;
Lasser, P .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (05) :487-493
[4]  
Imamura Hiroshi, 2001, American Journal of Gastroenterology, V96, P3178
[5]  
Japanese Gastric Cancer Association, 1999, JAP CLASS GASTR CARC
[6]  
KIM NK, 1993, CANCER, V71, P3813, DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO
[7]  
2-5
[8]   THERAPEUTIC SIGNIFICANCE OF NON-CURATIVE GASTRECTOMY FOR GASTRIC-CANCER WITH LIVER METASTASIS [J].
KOGA, S ;
KAWAGUCHI, H ;
KISHIMOTO, H ;
TANAKA, K ;
MIYANO, Y ;
KIMURA, O ;
TAKEDA, R ;
NISHIDOI, H .
AMERICAN JOURNAL OF SURGERY, 1980, 140 (03) :356-359
[9]   Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer [J].
Koizumi, W ;
Kurihara, M ;
Nakano, S ;
Hasegawa, K .
ONCOLOGY, 2000, 58 (03) :191-197
[10]  
Miyazaki M, 1997, AM J GASTROENTEROL, V92, P490